Detailed Narrative
Strong FY25 Performance Driven by Growth Across Segments
Zydus Lifesciences delivered a robust performance in FY25, with consolidated revenues reaching ₹232.4 billion, marking a 19% year-on-year growth. The company achieved its highest-ever operating profit and margins, with EBITDA growing 31% to ₹70.6 billion and operating margin expanding by 290 basis points to 30.4%. This strong profitability also significantly strengthened the balance sheet, moving from a net cash position of ₹8.6 billion in FY24 to ₹48.8 billion in FY25.
Q4 FY25 Momentum and Margin Expansion
The fourth quarter of FY25 continued this strong trajectory, with consolidated revenues of ₹65.3 billion, up 18% year-on-year and 24% quarter-on-quarter. Operating profitability saw significant improvement, with an EBITDA margin of 32.6%, an increase of 310 basis points year-on-year and 630 basis points quarter-on-quarter. EBITDA for the quarter stood at ₹21.3 billion, up 30% year-on-year and 53% sequentially, while net profit (adjusted) was ₹13.9 billion, up 18% year-on-year and 36% sequentially.
US Business and India Formulations Outperform
The US business registered revenues of ₹31.3 billion in Q4 FY25, growing 24% year-on-year and 30% quarter-on-quarter, driven by volume expansion and new product launches. The India geography, comprising formulations and consumer wellness, accounted for 39% of total revenues and grew 13% year-on-year. The branded formulation business in India grew 11% year-on-year, outpacing the market, with the chronic portfolio now contributing 43% as per IQVIA MAT March 2025, an improvement of 400 basis points over three years.
Strategic Focus on Specialty, Innovation, and Medtech
Zydus is expanding its specialty footprint in the US with 505(b)(2) products and a focus on pediatric rare diseases. The company's innovation pipeline is progressing, with USFDA approval for Phase II(b) clinical trial of Usnoflast and an expected read-out for Saroglitazar Magnesium for PBC by year-end. A significant strategic move includes the acquisition of a majority stake in Amplitude Surgical SA, France, marking an entry into the Medtech space, which is expected to be accretive for FY26-27.
FY26 Outlook: Growth with Margin Adjustment
For FY26, Zydus anticipates double-digit revenue growth overall, with the US business expected to grow in single digits and India business to outperform the market. However, EBITDA margins are guided to be around 26%, a reduction from FY25's 30.4%. This adjustment is attributed to competitive pressures on products like Revlimid, the loss of Asacol sales, and an increase in R&D expenses, which are projected to be 8% of revenue for FY26.
Product Pipeline and Regulatory Milestones
The company continues to focus on new product introductions, with 3 ANDAs filed, 6 approvals received, and 5 new products launched in Q4 FY25. In the vaccine R&D space, Zydus initiated development of a combination vaccine against shigellosis and typhoid with Gates Foundation support and received approval for a Phase 2 clinical trial for its Bivalent TCV vaccine. An exclusive development and commercialization agreement with Synthon BV for a novel 505(b)(2) oncology product, with NDA filing likely in 2026, further strengthens the specialty pipeline.